1. 175POverall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS). (25th November 2018) Authors: Shitara, K; Tabernero, J; Dvorkin, M; Mansoor, W; Arkenau, H-T; Prokharau, A; Alsina, M; Ghidini, M; Faustino, C; Gorbunova, V; Zhavrid, E; Nishikawa, K; Hosokawa, A; Ganea, D; Yalçın, Ş; Fujitani, K; Beretta, G; Winkler, R; Doi, T; Ilson, D H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA-002Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). (24th June 2018) Authors: Tabernero, J; Shitara, K; Dvorkin, M; Mansoor, W; Arkenau, H T; Prokharau, A; Alsina, M; Ghidini, M; Faustino, C; Gorbunova, V; Zhavrid, E; Nishikawa, K; Hosokawa, A; Ganea, D; Yalçın, Ş; Fujitani, K; Beretta, G; Winkler, R; Makris, L; Doi, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LBA25TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer. (23rd October 2018) Authors: Arkenau, H-T; Tabernero, J; Shitara, K; Dvorkin, M; Mansoor, W; Prokharau, A; Alsina, M; Ghidini, M; Faustino, C; Gorbunova, V; Zhavrid, E A; Nishikawa, K; Hosokawa, A; Ganea, D; Yalçın, Ş; Beretta, G D; Winkler, R E; Makris, L; Doi, T; Ilson, D H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗